Holen Sie sich die Stockscreener-App
12.17
4.85%
-0.62
Handel nachbörslich:
12.18
0.010
+0.08%
Schlusskurs vom Vortag:
$12.79
Offen:
$12.79
24-Stunden-Volumen:
1.72M
Relative Volume:
1.37
Marktkapitalisierung:
$738.44M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-13.23
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
+8.76%
1M Leistung:
+42.51%
6M Leistung:
+150.93%
1J Leistung:
+263.28%
1-Tages-Spanne:
$12.14
$13.09
1-Wochen-Bereich:
$10.85
$13.09
52-Wochen-Spanne:
$2.89
$13.85
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
12.17 | 738.44M | 65,400 | -46.34M | -38.74M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Boral Capital sets CorMedix stock target, Buy rating on potential By Investing.com - Investing.com Australia
Boral Capital sets CorMedix stock target, Buy rating on potential - Investing.com
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates - Yahoo Finance
CorMedix soars on Q4 preliminary results, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat - Investing.com India
CorMedix Soars 32% on Upbeat Q4 Forecast - Wall Street Pit
CorMedix Shares Rise 21% After Preliminary 4Q Results Beat Estimates - MarketWatch
CorMedix: Finally In Commercialization Mode (NASDAQ:CRMD) - Seeking Alpha
CorMedix soars on Q4 preliminary resyults, business updates - MSN
CorMedix stock soars on preliminary Q4 revenue beat By Investing.com - Investing.com Canada
CRMDCorMedix Inc. Latest Stock News & Market Updates - StockTitan
CorMedix soars on Q4 preliminary results, business updates (CRMD:NASDAQ) - Seeking Alpha
CorMedix Inc. Announces Preliminary Fourth Quarter 2024 Results and Provides Business Update - The Manila Times
CorMedix Hits Breakeven Target with $31M Q4 Revenue, Secures $25M in New Orders for DefenCath - StockTitan
Where are the Opportunities in (CRMD) - Stock Traders Daily
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year? - MSN
CorMedix price target raised to $12 from $11 at RBC Capital - Yahoo Finance
RBC optimistic on CorMedix shares as DefenCath launch gains traction in outpatient - Investing.com India
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock amid expansion plans - Investing.com Australia
CorMedix Inc. Added to Nasdaq Biotechnology Index - The Manila Times
CorMedix joins Nasdaq Biotechnology Index - Investing.com
CorMedix joins Nasdaq Biotechnology Index By Investing.com - Investing.com UK
CorMedix (CRMD) Earns Coveted Spot in Nasdaq Biotechnology Index in December Update - StockTitan
Is CorMedix Inc. (CRMD) Among Billionaire Paul Singer’s Top Long-Term Stock Picks? - Insider Monkey
CorMedix's SWOT analysis: defencath launch propels stock amid expansion By Investing.com - Investing.com Nigeria
CorMedix's SWOT analysis: defencath launch propels stock amid expansion - Investing.com India
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark - Simply Wall St
CorMedix's SWOT analysis: defencath launch boosts stock outlook By Investing.com - Investing.com South Africa
CorMedix's SWOT analysis: defencath launch boosts stock outlook - Investing.com
Closed System Transfer Device Market Size Poised to Hit USD 4,753.71 million by 2034, Driven by a 14.1% CAGR | PMR - GlobeNewswire Inc.
When (CRMD) Moves Investors should Listen - Stock Traders Daily
CorMedix Inc. Announces FDA IND Filing for Neutrolin(R) in United States - Marketscreener.com
CorMedix supports CMS policy updates - TipRanks
CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - The Manila Times
CorMedix: Major CMS Policy Change to Boost DefenCath Access for 30% of Dialysis Patients | CRMD Stock News - StockTitan
CorMedix Approves Key Governance and Incentive Changes - TipRanks
Cormedix EVP Elizabeth Hurlburt sells $1.57m in stock - Investing.com India
When the Price of (CRMD) Talks, People Listen - Stock Traders Daily
Nomura Holdings Inc's Strategic Reduction in CorMedix Inc Shares - GuruFocus.com
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns - Simply Wall St
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):